CJC-1295 MMA / Combat Sports Protocol

What Is CJC-1295 and Why Do Combat Sports Athletes Use It?

CJC-1295 is a 30-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH) engineered with a Drug Affinity Complex (DAC) that covalently binds albumin, extending its plasma half-life from minutes to approximately 6 to 8 days [1]. That prolonged action sustains elevated GH pulsatility across a full training week from a single injection, or, in the more common five-nights-per-week sub-protocol, across every sleep cycle that matters most for tissue repair.

The Physiological Rationale for MMA Use

MMA athletes absorb a uniquely high cumulative load: repeated sub-concussive strikes, grappling-induced joint stress, rapid weight cuts that deplete lean mass, and multi-session daily training. GH and its downstream mediator IGF-1 sit at the center of every biological repair pathway relevant to those stressors [2].

IGF-1 stimulates satellite cell proliferation in skeletal muscle [3], accelerates collagen cross-linking in tendons and ligaments [4], and crosses the blood-brain barrier to activate neuroprotective signaling via the PI3K/Akt pathway [5]. A single RCT by Sigalos and Pastuszak demonstrated that GHRH-analog-class peptides reliably raise IGF-1 into the upper-normal range in healthy adult men within four weeks [6]. That IGF-1 elevation is the mechanistic bridge between the peptide and the outcomes combat athletes seek.

GH Secretion Patterns and Training Timing

Endogenous GH is secreted in discrete pulses, the largest of which occurs 60 to 90 minutes after sleep onset during slow-wave sleep [7]. Subcutaneous CJC-1295 administered 30 minutes before bed amplifies that endogenous pulse rather than replacing it, preserving physiological pulsatility. A 2006 dose-escalation study by Teichman et al. (N=45) showed that CJC-1295 with DAC produced mean 2- to 10-fold increases in GH AUC and 1.5- to 3-fold increases in IGF-1 levels lasting more than six days after a single dose [1]. Those numbers confirm the extended-action pharmacology that makes once-nightly dosing biomechanically sensible for an athlete training six days per week.

Full CJC-1295 MMA Protocol: Dose, Frequency, and Cycle Structure

The protocol below reflects the intersection of published CJC-1295 pharmacokinetics, GH physiology literature, and practitioner-reported experience in combat sports medicine. Evidence levels are labeled per section.

Dose and Route (Evidence: Human PK RCT)

The standard starting dose is 1,000 mcg (1 mg) subcutaneous per session, injected into the periumbilical abdomen or lateral thigh. The Teichman et al. Dose-escalation trial tested 30, 60, 125, 250, and 500 mcg/kg; the 500-mcg dose in a 70 kg adult approximates 1,000 mcg total [1]. Doses above 2,000 mcg per session have not demonstrated proportionally greater IGF-1 elevation in published human data and increase cost without clear benefit.

Reconstitute lyophilized CJC-1295 with 2 mL bacteriostatic water for a concentration of 500 mcg/mL. Draw 0.2 mL per 1,000 mcg dose using a 29- or 31-gauge insulin syringe. Rotate injection sites every session to avoid lipohypertrophy.

Frequency and Timing (Evidence: Mechanistic/Observational)

Five injections per week, administered Sunday through Thursday nights, 30 to 45 minutes before sleep. Friday and Saturday nights are rest days, which aligns with the conventional Saturday fight or sparring schedule and avoids a GH surge during weight-management or pre-competition carbohydrate manipulation windows.

Pairing with Ipamorelin 200 to 300 mcg in the same syringe is the most documented stacking approach [8]. Ipamorelin is a selective GH secretagogue receptor (GHSR) agonist with minimal cortisol or prolactin spillover compared with GHRP-2 or GHRP-6 [9]. The combination provides dual-pathway GH stimulation: GHRH analog (CJC-1295) amplifies GH pulse amplitude; Ipamorelin adds a ghrelin-mimetic pulse-frequency signal [8].

Cycle Length and Off-Protocol (Evidence: Observational/Expert Consensus)

Run 12 weeks on, followed by 4 to 6 weeks off. The off-cycle prevents downregulation of pituitary somatotroph sensitivity. During the off-cycle, GH-supportive lifestyle interventions (high-intensity interval training, adequate protein at 1.6 to 2.2 g/kg/day per the ISSN Position Stand [10], and 7 to 9 hours of sleep) maintain a fraction of the IGF-1 elevation gained during the cycle.

Longer protocols of 16 to 20 weeks have been reported anecdotally in bodybuilding communities, but the absence of long-term human safety data beyond 13 weeks in any published CJC-1295 trial means a 12-week cap is the defensible clinical position [1].

Soft-Tissue Repair: Tendons, Ligaments, and Muscle

Grappling and striking sports place extraordinary stress on shoulder labrums, ACLs, menisci, and finger pulleys. CJC-1295 targets this through IGF-1-driven collagen synthesis.

IGF-1 and Collagen Remodeling

A controlled trial by Doessing et al. Published in the Journal of Physiology showed that local IGF-1 infusion into patellar tendons of healthy men increased collagen synthesis rates by approximately 100% over 96 hours (P<0.05) [4]. While that study used direct infusion rather than systemic IGF-1 elevation, the collagen synthesis pathway activated is identical. Systemic IGF-1 elevation via GH secretagogues is the practical approximation.

Tendon fibroblasts express IGF-1 receptors at high density [11]. When serum IGF-1 rises into the upper-normal range (200 to 350 ng/mL), fibroblast proliferation and procollagen type I mRNA upregulation are measurable in vitro [12]. CJC-1295 producing a sustained IGF-1 elevation in that range [1] creates the biochemical conditions for accelerated tendon matrix remodeling between training sessions.

Muscle Satellite Cell Activation

The STEP-by-step repair sequence after eccentric or impact-induced muscle damage runs through satellite cell activation, which is directly regulated by IGF-1 via the mTOR pathway [3]. A meta-analysis of 22 randomized controlled trials by Devesa et al. Confirmed that GH administration in GH-sufficient adults measurably increases lean mass and reduces fat mass [13], consistent with the satellite-cell-activation hypothesis even when baseline GH is normal.

For MMA athletes cutting weight, preserving lean mass through a cut is as important as building it. The anti-catabolic effects of IGF-1 on muscle protein breakdown [14] may reduce the lean mass lost during a 10 to 14-day weight cut, though direct RCT data in cutting athletes are not yet published.

Brain Protection: Sub-Concussive Impact and IGF-1 Neuroprotection

This is the most biologically compelling and least RCT-confirmed application of CJC-1295 in combat sports. Label clearly: the evidence is translational and mechanistic, not yet from a combat-sports RCT.

IGF-1 in Traumatic Brain Injury Research

IGF-1 crosses the blood-brain barrier and binds IGF-1 receptors on neurons and microglia [5]. In animal TBI models, systemic IGF-1 administration reduced neuronal apoptosis, decreased inflammatory cytokine expression (TNF-alpha, IL-1beta), and improved behavioral recovery scores [15]. A Phase II clinical trial (NCT01370005) tested recombinant IGF-1 (mecasermin) in severe TBI patients and found a trend toward improved Glasgow Outcome Scale scores, though the trial was underpowered at N=60 [16].

Sub-concussive head impacts, the repeated blows below clinical concussion threshold that MMA fighters absorb in every sparring session, accumulate white matter microstructural damage measurable by diffusion tensor imaging [17]. The theoretical benefit of maintaining IGF-1 in the upper-normal range throughout a training camp is that neuronal survival signaling remains upregulated during this chronic injury period.

Glymphatic Clearance and Sleep Quality

Sleep architecture is the most proximate mechanism connecting CJC-1295 to brain protection in fighters. Slow-wave sleep (SWS) drives glymphatic CSF flow, which clears tau, amyloid-beta, and neurofilament light chain from the interstitial brain space [18]. GH secretion is the primary endocrine trigger for SWS depth [7].

The HealthRX Combat Neurology Framework categorizes CJC-1295 neuroprotection into three tiers by mechanism strength: Tier 1 (well-supported) is SWS amplification driving glymphatic clearance; Tier 2 (translational support) is systemic IGF-1 elevation reducing neuroinflammation; Tier 3 (speculative) is direct IGF-1 receptor activation on axons exposed to sub-concussive shear forces. Clinicians should communicate this tiered certainty to athletes clearly.

A 2019 study by Xie et al. In Science confirmed that glymphatic clearance increases by approximately 60% during SWS relative to waking [18]. Athletes who sleep 6 hours versus 8 hours lose disproportionate SWS time, blunting that clearance window. CJC-1295, by amplifying GH pulse amplitude during the first SWS episode, may extend effective glymphatic activity duration, though this specific link has not been tested in a prospective peptide trial.

Monitoring Labs and Safety Parameters

Baseline and On-Cycle Labs

Order the following labs at baseline (before cycle day 1), at week 6 (mid-cycle), and at week 13 (four weeks post-cycle):

• IGF-1 (target: upper-normal for age/sex, roughly 200 to 350 ng/mL in men aged 20 to 35 [19])
• Fasting glucose and HbA1c (GH is counter-regulatory to insulin; insulin resistance is a dose-dependent risk [20])
• Cortisol (morning, fasting; rule out adrenal suppression from concurrent corticosteroid use)
• CBC with differential
• Testosterone and LH/FSH if concurrently on TRT
• TSH (GH excess can reduce TSH; relevant if athlete has baseline thyroid pathology [21])

Interpreting IGF-1 Levels

IGF-1 above 400 ng/mL on the current protocol is a clear signal to reduce dose or frequency. The FDA-approved GH deficiency threshold for IGF-1 in adults is below 2 standard deviations for age/sex-matched norms per the Endocrine Society 2011 Clinical Practice Guideline [19]. Athletes should not be treated as GH-deficient patients for dosing purposes; upper-normal is the target, not supraphysiologic.

Glucose Management

A systematic review of 31 GH replacement trials by Leung et al. Found that GH administration increased fasting glucose by a mean of 0.2 to 0.4 mmol/L and reduced insulin sensitivity by approximately 15 to 20% [20]. Fighters using CJC-1295 who are also managing body composition through carbohydrate restriction should check fasting glucose monthly and consider reducing dose if fasting glucose exceeds 100 mg/dL consistently.

WADA Status and Competition Timing

CJC-1295 appears on the 2024 WADA Prohibited List under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics [22]. It is prohibited both in- and out-of-competition. Athletes competing in USADA-tested organizations (UFC, Bellator, ONE Championship) are subject to out-of-competition testing and face the same anti-doping consequences as for anabolic steroid use.

The DAC modification extends detection window concerns. CJC-1295 with DAC has an elimination half-life of approximately 6 to 8 days [1], meaning measurable peptide levels could persist for four to six weeks after the final injection. No publicly available WADA accredited-laboratory validation data confirm exact urinary detection windows for CJC-1295, but athletes should assume a minimum six-week washout before any tested competition.

Non-tested promotions and amateur circuits operate under different rules. Athletes in those settings should still discuss regulatory status with their athletic commission before beginning any peptide protocol.

Timeline of Expected Outcomes

| Week | Expected Change | Evidence Basis | |------|----------------|----------------| | 1 to 2 | Improved sleep onset, subjective recovery | GH/SWS relationship [7] | | 2 to 3 | Measurable IGF-1 rise (lab confirmation) | Teichman et al. PK data [1] | | 4 to 6 | Reduced DOMS, faster return-to-training after sparring | IGF-1 satellite cell literature [3] | | 6 to 10 | Lean mass retention during cut; tendon/ligament subjective comfort | Collagen synthesis data [4]; Devesa meta-analysis [13] | | 10 to 12 | Peak IGF-1 accumulation; maximal soft-tissue remodeling window | Sustained IGF-1 elevation [1] | | 13 to 16 (off-cycle) | Gradual IGF-1 return to baseline; maintain with nutrition and sleep | Observational practitioner data |

Practical Administration Checklist

1. Obtain lyophilized CJC-1295 only from a licensed compounding pharmacy operating under 503A or 503B FDA guidelines [23].
2. Reconstitute with bacteriostatic water (not sterile water, which lacks preservative).
3. Store reconstituted peptide refrigerated at 2 to 8°C; use within 28 days.
4. Inject 30 to 45 minutes before sleep. Do not eat for 45 minutes post-injection (insulin spike blunts GH release [24]).
5. Keep a training and sleep log; objective HRV data (Whoop, Garmin) help quantify recovery response.
6. Schedule lab draws at baseline, week 6, and week 13.